Jeffrey Wong, MD, discusses the unmet needs in prostate cancer treatment, especially in regard to radiopharmaceuticals.

Medically reviewed by Matthew Wosnitzer, MD Castration-resistant prostate cancer (CRPC) is a type of advanced prostate cancer ...

A new study provides the strongest evidence to date on the clinical utility of a polygenic score for prostate cancer ...

Metastatic castration-resistant prostate cancer (mCRPC) treatment can involves chemotherapy, radiation, and more. Find the ...

Metastatic castration-resistant prostate cancer causes urinary symptoms, fatigue, pain, and more. This article covers the ...

Trisha Goddard’s appearance on Celebrity Big Brother while undergoing palliative treatment for stage 4 metastatic breast ...

The hope is the therapy can effectively target cancerous cells at relatively small doses while minimizing side effects.

The first patient in a phase 2 clinical trial evaluating 67Cu-SAR-bisPSMA for patients with metastatic castration-resistant ...

Dr Mohammad Mahmoud shares anticipated updates on evolving local treatments, PSMA-based therapies, and impactful genetic studies.

Residual cancer after neoadjuvant therapy predicts recurrence years later in men undergoing surgery for high-risk prostate cancer.

One-third of patients with PSA levels below 0.2 ng/mL after radical prostatectomy have recurrent disease identifiable by PSMA PET. More than one-third of patients with PSA levels less than 0.5 ng/mL ...